Conjugate Vaccine Market is projected reach US$ 27,015.3 Million by 2025 | Coherent Market Insights
Global Conjugate Vaccines Market
Increasing collaborations among the key market contenders aimed at developing and introducing vaccines for pneumococcal and meningococcal diseases in the global market, coupled with the ongoing clinical trials of the pneumococcal vaccines, are anticipated to fuel the growth of the global conjugated vaccines market in the near future. For instance, in April 2018, Merck & Co, Inc. initiated two Phase III studies of PCV-15 (V114), an investigational polyvalent conjugate vaccine for the prevention of pneumococcal disease.
The global conjugate vaccines market was valued at US$ 12,977.2 million in 2018, and is expected to witness a staggering 9.6% CAGR during the forecast period (2018-2026).
Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/2697
Figure 1. Global Conjugate Vaccine Market value Analysis (US$ Mn), By Product Type
Source: Coherent Market Insights Analysis (2019)
Increasing prevalence of various infectious diseases to boost the global conjugate vaccines market development
According to the World Health Organization (WHO), till November 2017, over 280 million people have been vaccinated with meningococcal A conjugate vaccine in around 21 African belt countries. In addition, surging prevalence of meningococcal infections is a major aspect expected to aid in growth of the global market. As reported by the Centers for Disease Control and Prevention (CDC), in 2015, around 375 cases of meningococcal disease were reported in the U.S.
Furthermore, development of multivalent conjugate vaccines by key players is expected to drive growth of global conjugate vaccine market. For instance, in September 2018, Pfizer, Inc. received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for its 20-Valent Pneumococcal Conjugate Vaccine (20vPnC) candidate, PF-06482077. The candidate has been developed for the prevention of invasive disease and pneumonia, caused by Streptococcus pneumonia serotypes for adults aged 18 years and older.
Increasing approvals for meningococcal conjugate vaccine candidates is further likely to boost the global market expansion. For instance, in December 2016, Pfizer Inc. received the European Commission (EC) approval for its expanded indication for Nimenrix (meningococcal group A, C, W-135, and Y conjugate vaccine), which is indicated for active immunization against invasive meningococcal disease (IMD), caused by Neisseria meningitidis serogroups A, C, W-135, and Y (MenACWY) in infants about six weeks old.
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CHRISTMAS2020” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/2697
Figure 2: Global Conjugate Vaccine Market Value (US$ Mn), By Region (2026)
Source: Coherent Market Insights Analysis (2019)
Global Conjugate Vaccines Market – Geographical Analysis
North America is expected to witness tremendous growth in the global conjugate vaccines market, owing to the burgeoning prevalence of diseases in the U.S. According to the 2015 report released by the National Health Interview Survey (NHIS), the risk of pneumococcal disease among adults in the U.S., aged between 19 years and 64 years, increased by 2.8% from 2014. Moreover, the presence of major vaccine manufacturers, such as Pfizer Inc. and others, in the region is another major growth propeller for the regional market.
Asia Pacific is expected to observe fast-paced growth in the global conjugate vaccines market, owing to the increasing initiatives taken by healthcare providers and hospitals. Moreover, various national governments in the region are focusing on vaccination programs to fulfil the demand. For instance, the National Immunization Program by Queensland Government in Australia and Mission Indradhanush vaccination program in India work to provide vaccination among children throughout the respective nations.
Furthermore, Europe is poised to expand significantly over the forecast timeframe, with the rising number of initiatives taken by the key market players for the development of conjugate vaccine systems in the region. For instance, in March 2015, Pfizer Inc. (U.S.) received the European Commission approval for an expanded indication for the use of Prevenar 13 (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) for prevention of pneumonia caused by the 13 pneumococcal serotypes in the vaccine in adults, aged 18 years and above.
Share your precise requirements @ https://www.coherentmarketinsights.com/insight/request-customization/2697
Global Conjugate Vaccines Market – Competitive Analysis
The leading players operating in the global conjugate vaccines market include Sanofi S.A, Pfizer, Inc., Merck & Co., Inc., GlaxoSmithKline Plc, Bharat Biotech, Serum institute of India Pvt. Ltd., Biological E. Limited, and Bio-Med.About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire